The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow
The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow for percutaneoustransluminal angioplasty (PTA) as well as the infusion of site-specificcontrast media for peripheral vascular anatomy (SCAN 2/15/95).The agency's most recent action allows Periflow to be marketedfor both PTA and the site-specific delivery of therapeutic pharmaceuticalsinto the peripheral vasculature. CVD, of Irvine, CA, plans tobegin U.S. shipments of Periflow by the end of this year.
In other news, Endosonics said CVD has received approval fromthe Japanese Ministry of Health to market its Controlled AngioplastyTechnology catheters in Japan.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.